Literature DB >> 15234341

Genetic variation in the multifunctional transcription factor Yy1 and type 1 diabetes mellitus in the BB rat.

Nora Klöting1, Ingrid Klöting.   

Abstract

Spontaneous diabetes in B(io)B(reeding) rats is complex, polygenic, and recessively inherited. Several crossing studies have demonstrated that beside the class II genes of the major histocompatibility complex (MHC, Iddm1) additional non-MHC genes are involved in diabetes development. One of them, Iddm4, was initially mapped on chromosome 6q32. To study the physiologic importance of Iddm4 a congenic BB.SHR rat strain (BB.6S) was established. The BB.6S is characterised by a drastic reduction of diabetes frequency (86 vs. 14%) indicating existence of diabetes protective genes of SHR on the exchanged chromosomal segment. One of the possible diabetes susceptibility candidate genes located within this exchanged region is the multifunctional transcription factor Yin yang 1 (Yy1). Yy1 was therefore sequenced in BB/OK and SHR rats. No genetic variation in exons between BB/OK and SHR was found. However, three single nucleotide polymorphisms (SNPs) were detected in intron 4. To determine the "wild type" allele, intron 4 of several diabetes-resistant inbred rat strains (DA, LEW, BN, and WOKW) and wild rats was sequenced. In addition, a congenic BB/OK strain was established by introgressing the same segment of chromosome 6 (D6Rat184-D6Rat3) of wild rats onto BB/OK background (BB.6W). The sequence analysis showed the SNP pattern of SHR (A/C/C) in all inbred rat strains studied whereas both unrelated wild rats showed the pattern of BB/OK rats (T/G/A). The congenic BB.6W rats developed diabetes in the same extent than BB/OK rats. This finding may support the assumption that the SNP pattern of BB/OK and wild rats favours and that of SHR suppresses diabetes development. Because of strong synteny between rat chromosome 6q32 and human 14q32, Yy1 may be also of interest in human type 1 diabetics showing significant linkage to markers on chromosome 14q32.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234341     DOI: 10.1016/j.ymgme.2004.04.007

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  5 in total

1.  Integrated computational and experimental analysis of the neuroendocrine transcriptome in genetic hypertension identifies novel control points for the cardiometabolic syndrome.

Authors:  Ryan S Friese; Chun Ye; Caroline M Nievergelt; Andrew J Schork; Nitish R Mahapatra; Fangwen Rao; Philip S Napolitan; Jill Waalen; Georg B Ehret; Patricia B Munroe; Geert W Schmid-Schönbein; Eleazar Eskin; Daniel T O'Connor
Journal:  Circ Cardiovasc Genet       Date:  2012-06-05

2.  Increase in Bone Mass Before Onset of Type 1 Diabetes Mellitus in Rats.

Authors:  Lyubomir Haralambiev; Andreas Nitsch; Cornelius S Fischer; Anja Lange; Ingrid Klöting; Matthias B Stope; Axel Ekkernkamp; Jörn Lange
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

Review 3.  Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review.

Authors:  Qun Chen; Wu-Jun Wang; Yun-Xuan Jia; Hao Yuan; Peng-Fei Wu; Wan-Li Ge; Ling-Dong Meng; Xu-Min Huang; Peng Shen; Tao-Yue Yang; Yi Miao; Jing-Jing Zhang; Kui-Rong Jiang
Journal:  Cell Biosci       Date:  2021-05-13       Impact factor: 7.133

4.  Risk variants disrupting enhancers of TH1 and TREG cells in type 1 diabetes.

Authors:  Peng Gao; Yasin Uzun; Bing He; Sarah E Salamati; Julie K M Coffey; Eva Tsalikian; Kai Tan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-25       Impact factor: 11.205

5.  Identification of novel diabetes impaired miRNA-transcription factor co-regulatory networks in bone marrow-derived Lin-/VEGF-R2+ endothelial progenitor cells.

Authors:  Mohammad R Irhimeh; Mohamed Hamed; Daniel Barthelmes; Yvonne Gladbach; Volkhard Helms; Weiyong Shen; Mark C Gillies
Journal:  PLoS One       Date:  2018-07-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.